Merck & Co., Inc. (NYSE:MRK)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research report issued to clients and investors on Friday, AnalystRatings.com reports. They currently have a $100.00 target price on the stock. Mizuho’s price target would indicate a potential upside of 24.63% from the stock’s previous close.
Other research analysts have also recently issued reports about the stock. Wolfe Research cut shares of Merck & Co., Inc. from an “outperform” rating to a “peer perform” rating in a report on Friday, June 12th. UBS Group decreased their target price on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating for the company in a report on Monday, April 13th. Morgan Stanley reiterated a “buy” rating and issued a $89.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 23rd. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Monday, June 8th. Finally, SVB Leerink decreased their price target on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, April 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. Merck & Co., Inc. currently has an average rating of “Buy” and a consensus price target of $94.15.
NYSE:MRK opened at $80.24 on Friday. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.64. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 0.82. The company has a 50-day moving average of $77.65 and a 200-day moving average of $79.99. The firm has a market cap of $202.53 billion, a price-to-earnings ratio of 14.48, a price-to-earnings-growth ratio of 2.24 and a beta of 0.48.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The company had revenue of $10.87 billion during the quarter, compared to analysts’ expectations of $10.52 billion. During the same period last year, the company posted $1.30 earnings per share. The business’s revenue for the quarter was down 7.6% on a year-over-year basis. On average, research analysts forecast that Merck & Co., Inc. will post 5.73 earnings per share for the current year.
In related news, EVP Julie L. Gerberding sold 36,285 shares of the firm’s stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $80.00, for a total transaction of $2,902,800.00. Following the transaction, the executive vice president now owns 62,862 shares of the company’s stock, valued at $5,028,960. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total transaction of $380,100.00. Following the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $387,702. The disclosure for this sale can be found here. 0.28% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of MRK. Total Clarity Wealth Management Inc. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. CBIZ Investment Advisory Services LLC raised its position in shares of Merck & Co., Inc. by 180.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock valued at $32,000 after purchasing an additional 271 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Merck & Co., Inc. in the second quarter valued at approximately $32,000. Lion Street Advisors LLC bought a new position in shares of Merck & Co., Inc. in the first quarter valued at approximately $35,000. Finally, Ruggie Capital Group bought a new position in shares of Merck & Co., Inc. in the first quarter valued at approximately $38,000. 74.26% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Article: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.